CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenue
Total operating revenue	$ 104,406	$ 94,666
Operating expenses
Selling, general and administrative expense	25,376	28,452
Depreciation and amortization	1,784	1,489
Total operating expenses	114,317	112,638
Total consolidated operating loss	(9,911)	(17,972)
Other non-operating expense (income)
Interest expense, net	5,570	1,985
Change in fair value of derivative warrant liabilities	43	0
Change in fair value of conversion option derivative liabilities	3,309	0
Other, net	752	(68)
Total other non-operating loss	9,674	1,917
Loss before provision for income taxes	(19,585)	(19,889)
Income tax expense	0	0
Net loss	$ (19,585)	$ (19,889)
Net loss per share attributable to common stockholders:
Basic (in usd per share)	$ (0.21)	$ (0.22)
Diluted (in usd per share)	$ (0.21)	$ (0.22)
Weighted-average number of shares outstanding:
Basic (in shares)	77,098,825	74,234,287
Diluted (in shares)	77,098,825	74,234,287
Patient services
Revenue
Total operating revenue	$ 53,068	$ 52,453
Operating expenses
Direct costs	47,080	49,497
Dispensary
Revenue
Total operating revenue	49,293	39,679
Operating expenses
Direct costs	39,863	32,809
Clinical trials & other
Revenue
Total operating revenue	2,045	2,534
Operating expenses
Direct costs	$ 214	$ 391